Analytik Jena and Fisher Scientific conclude a marketing and sales agreement

15-Jul-2008

Analytik Jena and Fisher Scientific have entered into a marketing and sales agreement for the German Market. The broad range of reagenetic equipment and instruments of the Jena Group will appear in future in the Fisher Scientific Sales Catalogue and then be distributed and sold via the Fisher Scientific sales staff.

The bio solutions' division of Analytik Jena AG is developing increasingly in the direction of being a system provider for bio-analytical applications and molecular diagnostics. The range of PCR- and detection appliances is being supplemented by reagenetic equipment, e.g. for DNA purification and laboratory- consumables and disposables, as well as by simple robotic systems. A total of 15 patents have been applied for during the past three years in this highly innovative industrial segment.

Mr. Klaus Berka, the CEO of Analytik Jena AG, offered this explanation: 'We anticipate significant impulses from these collaborative marketing and sales' activities within this still young area of bio solutions. We are extremely glad to have been able to gain the cooperation of Fisher Scientific for the marketing and sales of our well rounded product range.'

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper